Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: Report of a case

被引:4
|
作者
Kobayashi, Michiya [1 ]
Okamoto, Ken [1 ]
Nakatani, Hajime [1 ]
Okabayashi, Takehiro [1 ]
Namikawa, Tsutomu [1 ]
Ichikawa, Kengo [1 ]
Kitagawa, Hiroyuki [1 ]
Araki, Keijiro [1 ]
机构
[1] Kochi Med Sch, Dept Tumor Surg, Nankoku, Kochi 7838505, Japan
关键词
gastrointestinal stromal tumor; imatinib mesylate; tyrosine kinase inhibitor; c-kit mutation; stem cell factor;
D O I
10.1007/s00595-006-3224-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
A 49-year-old man underwent partial resection of the jejunum for an abdominal tumor, which was histologically confirmed to be a gastrointestinal stromal tumor (GIST). Immunohistochemistry revealed that the tumor cells were positive for c-kit, p52, and MIB-1. He underwent resection of a total of 83 recurrent tumors over the next 36 months. A computed tomography (CT) scan done a few months later showed multiple tumor recurrences. The patient was started on imatinib mesylate 400mg/day, and 3 months later, a CT image showed an increase in tumor size but a decrease in tumor density. Subsequent CT scans showed a marked decrease in tumor size 3 months later and no evidence of tumor recurrence 9 and 12 months after the commencement of imatinib treatment. The patient remains in complete remission 31 months after the start of treatment.
引用
收藏
页码:727 / 732
页数:6
相关论文
共 50 条
  • [41] Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
    Jason K. Sicklick
    Nicole E. Lopez
    Journal of Gastrointestinal Surgery, 2013, 17 : 1997 - 2006
  • [42] Imatinib treatment of gastrointestinal stromal tumors, 20 years later
    Le Cesne, Axel
    Verret, Benjamin
    Henon, Clemence
    Blay, Jean-Yves
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2023, 207 (06): : 716 - 721
  • [43] Gastrointestinal stromal tumors: Imatinib and beyond
    Schnadig I.D.
    Blanke C.D.
    Current Treatment Options in Oncology, 2006, 7 (6) : 427 - 437
  • [44] Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
    Sicklick, Jason K.
    Lopez, Nicole E.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2013, 17 (11) : 1997 - 2006
  • [45] Imatinib resistance in gastrointestinal stromal tumors
    Chen L.L.
    Sabripour M.
    Andtbacka R.H.I.
    Patel S.R.
    Feig B.W.
    Macapinlac H.A.
    Choi H.
    Wu E.F.
    Frazier M.L.
    Benjamin R.S.
    Current Oncology Reports, 2005, 7 (4) : 293 - 299
  • [46] Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
    Quek, Richard
    George, Suzanne
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 19 - 31
  • [47] Imatinib: Cost-effective in the treatment of gastrointestinal stromal tumors
    Finketstein, Stan N.
    Huse, Daniel M.
    Glendenning, G. A.
    Blanke, Charles D.
    Joensuu, Heikki
    von Mehren, Margaret
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
  • [48] Complete Pathological Response in Advanced Extra-gastrointestinal Stromal Tumor After Imatinib Mesylate Therapy: A Case Report
    Rediti, Mattia
    Pellegrini, Elisa
    Molinara, Elena
    Cerullo, Carmine
    Fonte, Carla
    Lunghi, Alice
    Iori, Alice
    Neri, Bruno
    ANTICANCER RESEARCH, 2014, 34 (02) : 905 - 907
  • [49] Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment
    Choi, Dongil
    Yoo, Eun Young
    Kim, Kyoung-Mee
    Sohn, Tae Sung
    Lee, Won Jae
    Lee, Ji Young
    Chang, Ilsoo
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (02) : W100 - W105
  • [50] Clinical Significance of Pathological Complete Response in Patients with Metastatic Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment - Lessons Learned
    Cheng, Chi-Tung
    Tsai, Chun-Yi
    Yeh, Chun-Nan
    Chiang, Kun-Chun
    Chen, Yen-Yang
    Wang, Shang-Yu
    Chen, Tsung-Wen
    Tseng, Jeng-Hwei
    Jung, Shih-Ming
    Chen, Tse-Ching
    Yeh, Ta-Sen
    ANTICANCER RESEARCH, 2014, 34 (11) : 6617 - 6625